FightAcne.com Interview with:
Michael H. Gold, M.D. FAAD
Gold Skin Care Center
Tennessee Clinical Research Center
FightAcne.com: What is the background for this study?
Response: What is the background for this study? Acne is a very prevalent disease; in fact, it is the most common thing seen in dermatologists’ offices across the country. We have not had a novel topical acne medication to treat both the inflammatory (papules and pustules) as well as the non-inflammatory acne (whiteheads and blackheads) for many years.
Clascoterone cream (1%) is that new breakthrough topical that we have been waiting for and has a unique mechanism of action in that it targets the androgen receptors in the skin. This unique treatment opportunity is the first new compound in over 40 years for dermatologists.